ESCMID: Sanofi's Nuvaxovid COVID-19 vaccine showed better tolerability than mNEXSPIKE in head-to-head study. First head-to-head, double-blind, randomized phase 4 study powered to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results